After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.
Biotech stocks remain pressured following the recent Brexit vote, which will make investing in these already highly volatile stocks even trickier. But there are opportunities too.
Stocks with insider trader activity include ELGX, SGEN and JYNT
Trade-Ideas LLC identified Seattle Genetics (SGEN) as a "perilous reversal" (up big yesterday but down big today) candidate
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.